Biosimilar drug makers settle IP spat over arthritis drug Humira
Clayton Utz 2020-01-21 2:21 pmBy Christine Caulfield | Melbourne
Please login to bookmark Close

German drug company Fresenius Kadi has resolved a patent case brought by Korean drug company Samsung Bioepis over a biosimilar of top selling arthritis drug Humira.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au